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Abstract: Taxane-derived agents are chemotherapy drugs widely employed in cancer 
treatment. Among them, paclitaxel and docetaxel are most commonly administered, but 
newer formulations are being investigated. Taxane antineoplastic activity is mainly based on 
the ability of the drugs to promote microtubule assembly, leading to mitotic arrest and 
apoptosis in cancer cells. Peripheral neurotoxicity is the major non-hematological adverse 
effect of taxane, often manifested as painful neuropathy experienced during treatment, and 
it is sometimes irreversible. Unfortunately, taxane-induced neurotoxicity is an uncertainty 
prior to the initiation of treatment. The present review aims to dissect current knowledge on 
real incidence, underlying pathophysiology, clinical features and predisposing factors 
related with the development of taxane-induced neuropathy. 
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1. Introduction 
Taxane is a family of antineoplastic agents discovered in the 1960s as a result of a National Cancer 
Institute screening program in which extracts from thousands of plants were tested for anticancer  
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activity [1]. Taxanes have broad-spectrum activity in solid tumor malignancies, and are currently used 
as first-line treatment for breast, stomach, lung, head and neck, prostate and gynecological  
malignancies [2], which represent highly prevalent tumors in the general population. Currently,  
taxane-based chemotherapy schedules are a first-line treatment in both early-stage and metastatic breast 
cancer [3], the most common malignant tumor in women, occurring in one out of every eight women in 
her lifetime. Furthermore, recent research from experimental and clinical trials has demonstrated 
potential therapeutic effects of some type of taxane in several non-cancer diseases [4]. 
Paclitaxel and docetaxel were the initial prototypic taxane agents introduced into clinical practice, 
and they are two of the antineoplastic drugs currently in widest use. Paclitaxel was originally extracted 
from the bark of the yew tree (Taxus brevifolia) in the western region of the United States [1]. The most 
commonly used commercial preparation of paclitaxel is Taxol® (Bristol-Myers Squibb; New York, NY, 
USA). This is a semisynthetic agent derived from the precursor 10-deacetylbaccatin III produced from 
the needles of European yew tree Taxus baccata. Docetaxel is a semisynthetic paclitaxel derivate 
commercialized under the trade name Taxotere® (Sanofi-Aventis; Paris, France). Both paclitaxel and 
docetaxel consist of a complex taxane ring linked to an ester at the C-13 position [1] (Figure 1). Both share 
hydrophobic properties, requiring solvents for their administration: Cremophor® EL (polyethoxylated 
castor oil, CrEL) for paclitaxel and polysorbate-80 for docetaxel. These solvents have been related with 
frequently observed allergic reactions [1,5]. Extensive research in new analogs and new formulations 
with better therapeutic and toxicity profiles, and higher solubility, is underway. The second-generation 
of taxane includes nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane®) and 
cabazitaxel (Jevtana®), a semi-synthetic derivative of docetaxel, which have recently been incorporated 
in the antineoplastic armamentarium [5,6]. Liposomal paclitaxel formulations (i.e., Genexol®-PM) and 
other drug delivery systems are being investigated [7]. 
 
Figure 1. Chemical structure of paclitaxel (A) and docetaxel (B)  
(Source: http://pubchem.ncbi.nlm.nih.gov). 
Paclitaxel and docetaxel are both associated with two main types of toxicity: peripheral neurotoxicity 
(NTX) and myelosuppression [1]. Whilst hematological toxicity can become lesser with the concurrent 
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use of granulocyte colony-stimulating factors during chemotherapy, the occurrence of peripheral nerve 
toxicity represents one of the Achilles’ heels of taxane treatment. In one study including adjuvant or 
neoadjuvant breast cancer patients, dose-modification of taxane planned schedule was performed due to 
peripheral NTX in 17% of patients [8]. 
Taxane-induced peripheral neuropathy (TIPN) is problematic for several reasons. First, it is a growing 
issue due to improved long-term cancer survival. More cancer patients live longer or are cured due to 
the greater effectiveness of new drugs and therapeutic regimes. Second, receiving a complete taxane 
regimen is probably a critical factor in determining the outcome of a given cancer patient. TIPN is a 
dose-limiting side effect that must be considered when treating cancer patients with these agents, 
decreasing total cumulative dose administered [9], which may impair cancer outcome. Third, TIPN 
negatively impacts on routine activities, functions, and behaviors in the domestic, work, and 
social/leisure lives of cancer patients, adversely compromising the quality of the survivorship [10]. 
Finally, the development of TIPN is associated with an increase in the overall cost of cancer care for 
healthcare systems [11]. The present review is an attempt to dissect current knowledge on incidence, 
underlying pathophysiology, clinical features and predisposing factors related with the development  
of TIPN. 
2. Epidemiology of TIPN 
The incidence of all grades of TIPN among those patients treated with paclitaxel is high, ranging from 
57%–83% overall and with severity in 2%–33% of patients [12]. Likewise, incidences reported with 
docetaxel are also highly variable: 11%–64% and 3%–14% overall and severe, respectively [13–15]. 
Although paclitaxel is classically considered more neurotoxic than docetaxel [8,16,17], one phase III 
clinical trial comparing paclitaxel 175 mg/m2 vs. docetaxel 100 mg/m2 every 21 days until progression 
or toxicity, reported a greater overall incidence of neuropathy in the docetaxel group (64.4% vs. 59%) 
and more frequent although, not significantly so, severe neuropathy (7.4% vs. 4.1%, p = 0.08) [14]. The 
substantial heterogeneity in reported rates when reviewing the literature can be partially explained by 
the differences in taxane schedules and the manner of NTX assessment [18]. The scales commonly used 
to evaluate TIPN employ a combination of subjective and objective items that are not always 
unambiguously described leading to variable interpretation. The limitations of the National Cancer 
Institute common toxicity criteria (NCI.CTC), including inconsistencies and broad generalization, 
explain much of the existing epidemiological confusion. Recently, one homogeneous study including 
more than 4500 breast cancer patients treated with taxane in the adjuvant setting reported an incidence 
of grades 2–4 NCI.CTC neuropathy according to as follows: 22% in paclitaxel weekly; 17.4% in 
paclitaxel every three weeks; 14.7% in docetaxel every three weeks; and 13.4% in docetaxel  
weekly-arm [19]. Of note, reported incidences emerge more clearly when detailed neurological 
examination is performed and neurological scales, such as the Total Neuropathy Score (TNS), are 
included in the TIPN assessment [20,21]. Pace et al. reported an incidence of 71% and 96% at 12 and 
24 weeks of weekly-paclitaxel, respectively, assessed with neurologic and neurophysiological 
evaluation [22]. Published neuropathy incidence and severity also seem greater when patient-reported 
outcome measures are considered in TIPN assessment [23]. 
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Regarding the second generation of taxane, phase III clinical trials comparing standard paclitaxel 
with nab-paclitaxel in breast cancer showed higher incidence of grade 3 neuropathy in nab-paclitaxel 
than in the standard treatment (10% vs. 2%) [24]. Conversely, lung cancer patients showed opposite 
ratios, 3% and 12% for nab-paclitaxel and standard treatment, respectively [25], in patients. On the other 
hand, an overall incidence of TIPN of 7.2%–14%, and a low-rate (1%) of severe neuropathy with 
cabazitaxel in the treatment of prostate cancer, have been consistently reported in clinical trials [26,27]. 
Finally, NTX rates up to 35% with liposomal paclitaxel formulation have been reported [28]. 
3. Pathophysiology of TIPN 
Taxane belongs to a group of chemotherapy agents defined as “microtubule stabilizing agents” [29]. 
Taxane targets the cytoskeleton and spindle apparatus of tumor cells by binding to the microtubules, 
which are fibrillary polymers of α- and β-tubulin monomers. Taxane promotes microtubule assembly by 
stabilizing the polymerization of β-tubulin into bundles. This action disrupts mitotic spindles and arrests 
the cell cycle in the G0/G1 and G2/M phases leading to apoptosis in dividing cells [4,30,31]. However, 
neurons are quiescent cells. The exact pathophysiologic mechanism of TIPN is not well understood [32]. 
The inhibition of tubulin depolymerization and the consequent microtubule dysfunction seems the most 
widely accepted mechanism related with the taxane neurotoxic profile [32–35]. Intact microtubules are 
required for both anterograde and retrograde axonal transport, and neuronal survival and function depend 
on these transport processes. Increased axonal microtubule stability or polar reconfiguration [36] 
secondary to taxane might alter the retrograde axonal transport of growth factors, or other substances 
resulting in abnormal nerve physiology, and altered mitochondrial supply, leading to a loss of axonal 
integrity, or axonal degeneration in more severe cases. This phenomenon begins in the most vulnerable 
part of the nerve, the distal nerve endings of the longest nerves, where transport problems may manifest 
most quickly, and after this it spreads centrally, similar to other ‘dying back’-type peripheral 
neuropathies [33,34]. 
Paclitaxel does not cross the blood brain barrier, and its accumulation in the soma of sensory neurons 
of dorsal root ganglia (DRG) is presumably due to the relative deficiency in the blood–nerve barrier also 
observed in this region [34]. Microtubule impairment in the soma of the sensory neurons has been  
noted [34,37]. Furthermore, increased excitability of primary sensory neurons in DRG of animal models 
and changes in gene expression of some neuronal ion channels in DRG have recently been implicated 
in the development of paclitaxel-induced neuropathy [38]. 
Motor neurons are not as sensitive to taxane as sensory neurons are, despite their similar length. The 
mechanism by which taxane produces a preferential impairment of sensory neurons remains  
unclear [32]. Special vulnerability compared with motor neurons in the anterior horn of spinal cord was 
suggested [39]. Recent studies showed that mitochondria in sensory axons are more susceptible to the 
toxicity of paclitaxel compared to mitochondria in motor axons, providing a potential hypothesis for this 
fiber selectivity [40–42]. According to mitotoxicity hypothesis, the mitochondrial injury would lead to a 
chronic energy deficit in the axons causing abnormal spontaneous discharges and compartmental 
degeneration in somatosensory primary afferent neurons and that could be the common denominator in 
many distal symmetrical sensory neuropathies of different origin [42,43]. It has been attributed to the 
binding of paclitaxel to mitochondrial β-tubulin, which may produce Ca2+ release from mitochondria 
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and dysregulated intracellular Ca2+ homeostasis [40]. However, why mitochondrial dysfunction in 
primary afferent sensory neurons would be predominant compared with other tissues with high energetic 
consumption is unresolved [32,42]. 
Another unanswered question is the pathogenic mechanisms underlying acute NTX related with 
taxane (see below), because this kind of NTX most likely is not primarily due to disorganization of 
microtubules and consequent disruption of axoplasmic flow in peripheral nerves [44]. The called 
“paclitaxel acute pain syndrome” (PAPS) has been related with a sensitization of nociceptors and their 
fibers by proinflammatory cytokines (IL-6, IL-8, IL1β, TNF-α) prior to the development of  
neuropathy [45–47]. 
On the other hand, morphological nerve changes observed in the only four patients treated with 
paclitaxel [48–50] and docetaxel [51] we are aware have been described in the literature in whom sural 
nerve biopsy was performed after finishing chemotherapy, showed severe nerve fiber loss, axonal atrophy, 
and secondary demyelination with a preferentially loss of large myelinated fibers [48]. Evidence of 
axonal regeneration was present in docetaxel [51] but not in paclitaxel [48–50]. Intriguingly, no 
aggregation of microtubules was observed on sural nerve biopsies from these patients [48–50]. 
Although it is well established that taxane affects large myelinated fibers (Aβ), the involvement of 
small myelinated (Aδ) and unmyelinated (C) sensory fibers is more controversial [31,44]. Experimental 
evidence shows that after paclitaxel infusion, pathological features occur in less than 5% of small DRG 
neurons and 30%–40% of large DRG neurons [52]. In patients, one clinical study including neurological 
examination and quantitative sensory testing showed predominant impairment of large myelinated 
fibers, intermediate impairment of Aδ fibers, and relative sparing of unmyelinated fibers [44]. Although 
there are numerous studies demonstrating loss of intraepidermal nerve fiber density (IEFND), a marker of 
small fiber impairment, in foot pad of animals treated with paclitaxel [53,54], evidence from patients is 
scarce. To our knowledge, only three pathological studies in patients evaluating small-fiber impairment by 
skin biopsy have been reported in the literature, with conflicting evidence. In one, including six patients 
prospectively assessed during treatment, the authors found an increase in all but one patient of IEFND 
during chemotherapy treatment [55]. A recently published cross-sectional study with 20 breast cancer 
women with established docetaxel-induced peripheral neuropathy reported a high proportion (15/20) of 
patients with loss of IEFND according to normative data [56], supporting small fiber involvement in the 
neuropathy due to docetaxel. Regarding paclitaxel, to our knowledge, available evidence is limited to 
one patient recently reported demonstrating a clear decrease in both Meissner’s corpuscule and IEFND 
densities as compared with healthy control subjects [57]. 
4. Clinical and Neurophysiological Pattern of TIPN 
Patients undergoing taxane treatment may present two types of peripheral NTX: acute transient and 
subacute long-lasting TIPN. Paclitaxel and docetaxel are associated with an acute pain syndrome in up 
to 70% of patients [46], consisting of diffuse muscle aching, most often in the legs, hips, and lower back, 
although it can be widespread, regarded as myalgia or arthralgia that usually develops within one to 
three days of drug administration and usually resolves within a week [58–60]. Acute NTX is more 
frequently observed with short and high-dose infusions [46,61]. Despite its transient nature, it is highly 
distressing especially for paclitaxel-treated patients [60]. Interestingly, an association between the presence 
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and severity of the PAPS and the further development of painful neuropathy has been reported. One 
detailed prospective study dissecting natural history of PAPS with 94 patients receiving paclitaxel 
reported that the initial intensity of pain experienced within the first week after the first dose of paclitaxel 
was predictive of the severity of shooting/burning pain symptoms of TIPN [46]. 
Long-lasting TIPN is characterized by symmetrical onset of sensory symptoms usually first in the 
tips of the toes and afterwards in the fingers, although simultaneous development in both the fingers and 
toes is not infrequent [21,44,62]. Sensory disturbance extends to soles and palms [44]. Facial 
involvement is less common, although anecdotally reported. In order of frequency, paclitaxel and 
docetaxel display a similar pattern of induced sensory symptoms including numbness (100%), tingling 
(80%), sensitivity to cold (60%) and neuropathic pain (50%) [44,60,62]. Loss of balance is also a 
complaint made by over 50% of patients [60]. Neurological examination consistently shows a loss of 
reflexes. Although initially only ankle reflexes are lost, global arreflexia is common. Of note, despite 
typical greater involvement of large diameter fibers, measurement of the vibration perception threshold 
seems not to be a reliable indicator of neuropathy and may be normal in many patients with TIPN [62]. 
Variable changes in pinprick and temperature sensibility can be found [44,62,63]. Romberg’s sign may 
be present in those patients most severely affected. Treatment with docetaxel has been associated with 
Lhermitte’s sign [62]. Conversely, motor impairment is unusual although muscle cramps, and distal 
muscle loss of strength may be observed. At high doses, proximal weakness can develop with severe 
muscle aches [64,65]. Nevertheless, when evident clinical motor signs occur, assessment by a neurologist is 
recommended to rule out other entities [65,66]. Symptoms associated with changes in autonomic 
function are infrequent but must be specifically interviewed in patients receiving taxane [62]. Autonomic 
cardiac and vascular dysfunction in the form of arrhythmias and orthostatic hypotension induced by 
paclitaxel have been reported [67], and demonstrated in comparative studies evaluating heart-rate 
recordings before and after taxane administration, with paclitaxel [68–70], but not with docetaxel [71]. 
Regarding time to onset of TIPN, paclitaxel induced neuropathy with one- and three-week schedules 
is reported to develop in 21 days (range 11–101) and 35 days (range 14–77), respectively [72]. Although 
a very early onset of grade 2 neuropathy after the first cycle of docetaxel can occur in up to one third of 
patients [15,44,62,72], one study comparing paclitaxel (175 mg/m2) and docetaxel (75 mg/m2) 
administered every three weeks found that the severity of TIPN peaked earlier (cycle 3 to cycle 7) in 
patients receiving paclitaxel compared with those receiving docetaxel (cycle 5–7 months) [73]. Further 
progression of neuropathy after finishing chemotherapy during 1–2 months (coasting effect) has been 
described with both agents [62]. 
Electrophysiological abnormalities when TIPN develops show an axonal peripheral neuropathy 
pattern, mainly involving the decrease of sensory nerve action potential or abolishment of sensory 
responses in sensory conduction studies. Reduction of compound motor action potential occurs at the 
highest cumulative doses, or may be normal in most cases, while sensory and motor nerve conduction 
velocity is usually spared. Needle electromyography may show variable amounts of abnormal 
spontaneous activity related with denervation depending on the severity of the neuropathy and degree of 
motor fiber involvement [62,65,66]. 
TIPN is considered to have an overall good long-term prognosis [66]. Despite appearing to be largely 
reversible, long-term studies with large follow-up reveal significant rates of persistent TIPN although 
usually well tolerated [74,75]. Overall, approximately half of patients with TIPN completely recover 
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within the first year [72,73], to a lesser extent in those receiving docetaxel which seems to present more 
frequent severe residual TIPN compared with paclitaxel at 12 months [73]. However, most reported 
studies are retrospective in nature [66,75], include a highly variable frame of observation period of  
time [66,74,75] or variable manner of NTX gradation [66,73], which compromises comparison of reported 
frequencies among them.  
5. Risk Factors for TIPN 
Not all cancer patients receiving taxane will develop TIPN. Moreover, among those patients affected, 
even in the setting of uniform insult, there is considerable difference in the severity of NTX. Reasons 
underlying this variability are partially known, and there are no established, validated predictive 
biomarkers to determine which patients are at greater risk for TIPN. Furthermore, diagnosing and 
assessing symptoms related to TIPN in daily practice is complex and typically the physician goes after 
clinical syndrome. In particular, NTX in metastatic breast cancer patients receiving paclitaxel can be 
problematic because treatment is frequently administered until progression or toxicity, as a common 
approach. In general, chemotherapy-related and patient predisposing conditions should be considered 
before treatment with taxane in cancer patients. 
5.1. Treatment Related Risk Factors 
Total cumulative dose and dose intensity are considered the more important determinants of incidence 
and severity of NTX, as in other chemotherapy-induced peripheral neuropathies [18]. Onset doses for 
neuropathy of any grade range from 100–300 mg/m2 and 75–100 mg/m2 with paclitaxel and docetaxel, 
respectively [13]. In a randomized phase III study of metastatic breast cancer, the mean cumulative dose 
leading to onset of grade 2 peripheral NTX was 371 mg/m2 for docetaxel and 715 mg/m2 for paclitaxel [14]. 
Generally, severe TIPN occurs in patients receiving cumulative doses around 1000 mg/m2 for paclitaxel 
and 400 mg/m2 for docetaxel [29]. Traditionally, weekly paclitaxel schedules have been associated with 
higher NTX than tri-weekly schedules [76,77]. However, other studies comparing weekly and  
three-weekly paclitaxel schedules failed to find this association [72], including two recent meta-analyses 
of the available evidence from randomized controlled trials that observed less NTX with weekly 
paclitaxel compared with three-weekly schedules [78,79]. The relationship between weekly and  
every-three-week administration of docetaxel and NTX is uncertain, as studies have shown conflicting 
results [80,81]. The NTX induced by paclitaxel is also infusion-duration related, and most frequently 
occurs when paclitaxel is infused over 3 h instead of 24 h, suggesting that NTX is related to peak plasma 
concentration [82]. However, one study comparing weekly paclitaxel infused in 1 h or 3 h reported 
comparable frequency of NTX [83]. 
Notwithstanding, the administration of multiple neurotoxic agents concurrently is not uncommon in 
oncology practice. Co-administration of paclitaxel with cisplatin, which is a common schedule in a 
variety of cancers, showed that nearly the totality (95%) of patients developed peripheral NTX [65]. 
Concurrent treatment of taxane with other neurotoxic agents seems to induce a synergistic effect more 
than an additive one. Another study including 63 patients treated with docetaxel and cisplatin in which 
NTX was prospectively assessed in detail revealed that the neurotoxic effects of this combination were 
more severe than either cisplatin or docetaxel as a single agent at similar doses [62]. Another study 
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comparing the safety of weekly cisplatin with or without paclitaxel demonstrated that the odds ratio for 
NTX was 8.3 for paclitaxel coadministration [84]. Regarding non-neurotoxic agents sometimes 
administered concurrently with taxane, bevacizumab has not been shown to modify the risk for  
NTX [85–87] despite experimental evidence supporting a potential NTX-inducing role [88]. 
5.2. Patient Predisposing Risk Factors 
Demographic characteristics of patients receiving taxane have also been investigated to search for 
risk factors associated with TIPN development. Whereas it has been suggested that elderly people were 
more prone to developing TIPN [89,90], many studies have failed to observe such association [15,62,91] 
including the largest epidemiologic retrospective study published of breast, lung and ovarian cancer [92]. 
Regarding severity, more severe TIPN also seems not to be related with age of patients [91]. 
Nevertheless, one retrospective study evaluating duration of NTX induced by paclitaxel reported longer 
persistence of neuropathy in older patients (>60 years) [72]. In regard to race differences in TIPN, several 
paclitaxel studies show a higher associated risk of NTX in the African-American population [8], and 
found that non-Europeans were at significantly higher neuropathy risk than Europeans of similar 
genotype [93]. 
The putatively higher associated risk of TIPN in patients with pre-existing neuropathy is difficult to 
evaluate since the majority of clinical trials routinely exclude these patients. Whilst a statistically 
significant association was observed for early peripheral NTX induced by docetaxel and preexisting 
neuropathy [15], other studies failed to find this association [16,92]. More agreement exists regarding 
patients with the hereditary neuropathy Charcot-Marie-Tooth (CMT) being poorly tolerant of  
paclitaxel [16,94]. Furthermore, conflicting evidence regarding the potential higher-risk of TIPN in 
patients suffering from diabetes mellitus is also present in the literature [8]. Importantly, a lack of 
information concerning concurrent peripheral neuropathy secondary to diabetes is common and critical 
in these studies. 
In addition, the role of tumor-related characteristics associated with TIPN has also been investigated. 
In one study including more than 1700 breast cancer patients, those who developed early docetaxel 
peripheral NTX more frequently had tumors less than 2 cm and node-negative disease [15]. However, 
most studies (all retrospective) including patients treated with paclitaxel and docetaxel [8,72] did not 
find any significant association of variables related with tumor type, extension and time to or duration 
of TIPN [72]. 
Finally, there is growing evidence that chemotherapy-related toxicity is an inheritable trait, and the 
genetic signature of a predisposition to TIPN is increasingly being investigated. Several studies have 
identified genetic polymorphisms associated with TIPN, most of them with inconclusive  
results [95–100], and only few accompanied with replication or validation studies [101–103]. Overall, 
polymorphisms in genes involved in the drug metabolism, distribution, and elimination properties of 
taxanes have been shown to be relevant for TIPN [102]. More recently, the role of genes involved in 
regulation of axon outgrowth [98] and genes associated with congenital neuropathies  
(Charcot-Marie-Tooth disease) [99] have been also reported in large prospective studies. However, the 
available data need to be interpreted with caution because of several limitations in the available studies, 
including the implementation of post-hoc analysis of oncology-based databases of different, not  
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pre-planned size and inappropriate outcome measures for neurological impairment. For these reasons, it 
is not recommendable to adopt decisions on treatment on the basis of the current evidence on genomics. 
6. Neuroprotection Strategies and Symptomatic Treatment for TIPN 
Multiple strategies to prevent TIPN have been investigated, but no therapy has been definitely proven 
in randomized controlled trials to be beneficial for preventing the paclitaxel-associated acute pain 
syndrome or long-lasting TIPN. Among the strategies studied are acetyl-L-Carnitine, amifostine, 
amitriptyline, glutamate, glutathione, leukemia inhibitory factor, omega 3, corticosteroids, retinoid acid 
and Vitamin E [104–108]. 
Treatment of established TIPN aims to relieve disturbing symptoms such as neuropathic pain, 
numbness, and tingling. The types of drugs usually recommended by physicians include topical analgesics, 
antidepressants, and anticonvulsants, despite the lack of data from prospective placebo-controlled trials. 
Up to now, evidence concerning their effectiveness is scarce or negative [104,109]. Most robust evidence 
for treatment of TIPN emerges from a large randomized, double-blind, placebo-controlled phase III trial 
with duloxetine (60 mg/daily), which was shown to be modestly but significantly effective in diminishing 
TIPN-related pain [110]. In this trial, duloxetine, a selective serotonin and norepinephrin reuptake inhibitor 
used in depression and in diabetic neuropathy, was demonstrated to be more effective than placebo in 
chemotherapy-induced peripheral neuropathic pain, including 87 (40%) of patients treated with  
paclitaxel [110]. Of note, the exploratory subgroup analysis of the study suggested that duloxetine may 
work better for patients with painful oxaliplatin-induced, as opposed to painful TIPN. Importantly, attention 
was paid to the potential interaction of duloxetine in breast cancer patients with TIPN receiving 
tamoxifen, due to the fact that duloxetine inhibits CYP P450 2D6 enzyme, which is necessary to correct 
the conversion of tamoxifen to its active metabolite, endoxifen [110]. 
7. Conclusions 
TIPN is of major concern for physicians and patients due to the negative consequences in terms of 
cancer outcome and quality of life. New taxane formulations are being developed to improve 
antineoplastic properties and minimize toxicities, but NTX remains an unsolved problem. There are 
limited data available describing risk factors of NTX, mainly epidemiologic and obtained from 
retrospective studies. Increased knowledge from pharmacogenomics studies is being investigated 
regarding inherited risk associated with TIPN development. However, knowledge of these risk markers 
is still far from being considered in clinical practice, and multiple considerations must be made before 
denying taxane treatment to candidate cancer patients based on the potential NTX savings. In this line, 
prospective neurological monitoring including subjective and objective clinical and neurophysiological 
data might be useful, as demonstrated in toxic neuropathies induced by oxaliplatin [111] and  
bortezomib [112]. The early identification of patients at risk of severe NTX by neurological monitoring 
could be useful to allow prompt reductions of the dose of taxane before irreversible or severe nerve 
damage occurs. Furthermore, knowledge of these predictive biomarkers may be critical to improving 
design of future clinical trials to test neuroprotective strategies against TIPN, which remains as a need. 
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